Chemokine CXCL10’s role in the immune response to SARS-CoV-2
| Autor: | Hannah Ivester, Holly Morrison, Carla Finkielstein, Nisha Duggal, James Weger, Irving C Allen |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | The Journal of Immunology. 208:125.33-125.33 |
| ISSN: | 1550-6606 0022-1767 |
| Popis: | Since the beginning of the SARS-CoV-2 pandemic in early 2020, it was apparent that one of the most striking clinical features of the disease caused by the virus, COVID-19, was the lung damage that occurs. This lung damage is often the result of an immune response gone awry as the host attempts to clear the virus. This overactive immune response, the ‘cytokine storm,’ is responsible for much of the most severe cases of COVID-19 as well as the Multisystem Inflammatory Syndrome in pediatric patients. Since the start of the pandemic, a few key players have been identified in the progression of COVID-19 disease as well as the immune response to it. These include pro-inflammatory cytokines IL-6, TNF-alpha, and CXCL10. Many clinical reports have especially shown the importance of the chemokine CXCL10 as a prognostic biomarker with patients having higher levels of CXCL10 often having more severe outcomes. Recent studies have also shown an increase in CXCL10 and its associated pathways in animal models of COVID-19. Here we continue to provide evidence for the importance of the protein CXCL10 in SARS-CoV-2 immunity through whole genome transcriptomics studies in human and k18-hACE2 mice. Following these, further studies with a mouse-adapted SARS-CoV-2 virus and Cxcl10−/− mice also showed a decreased level of effectiveness in viral clearance in the absence of effective CXCL10. These data continue to show the importance of the chemokine CXCL10 in both disease severity and viral clearance of SARS-CoV-2 infection adding to the growing body of evidence related to SARS-CoV-2 pathobiology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|